OP0224 RESULTS OF A PHASE 2 STUDY OF RG6125, AN ANTI-CADHERIN-11 MONOCLONAL ANTIBODY, IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INADEQUATE RESPONSE TO ANTI-TNFALPHA THERAPY

Efficacy and Safety of E6011, an Anti-Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3523879 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Efficacy and Safety of E6011, an Anti‐Fractalkine Monoclonal Antibody, in Active Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate: Results of a Randomized, Double‐blind, Placebo‐controlled Phase 2 study

Arthritis & Rheumatology ◽

10.1002/art.41555 ◽

2020 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Inadequate Response ◽

Phase 2 ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

OP0025 Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.1708 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 61.1-61 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

M.E. Weinblatt ◽

J.S. Smolen

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Methotrexate Therapy ◽

Phase 2 ◽

Double Blind ◽

Double Blind Placebo ◽

SAT0126 A PHASE 2 STUDY OF E6011, AN ANTI-FRACTALKINE MONOCLONAL ANTIBODY, IN PATIENTS WITH RHEUMATOID ARTHRITIS INADEQUATELY RESPONDING TO BIOLOGICS

10.1136/annrheumdis-2019-eular.1894 ◽

2019 ◽

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase 2 ◽

A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs

Modern Rheumatology ◽

10.1080/14397595.2020.1868675 ◽

2021 ◽

pp. 1-11

Author(s):

Yoshiya Tanaka ◽

Tsutomu Takeuchi ◽

Hisashi Yamanaka ◽

Toshihiro Nanki ◽

Hisanori Umehara ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase 2 ◽

Disease Modifying Antirheumatic Drugs ◽

Antirheumatic Drugs ◽

Phase 2 Study ◽

Disease Modifying

THU0100 Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-eular.2065 ◽

2013 ◽

Vol 71 (Suppl 3) ◽

pp. 188.1-188 ◽

Cited By ~ 4

Author(s):

B. Hsu ◽

S. Sheng ◽

J.S. Smolen ◽

M.E. Weinblatt

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Methotrexate Therapy ◽

Phase 2 ◽

Proof Of Concept ◽

Double Blind ◽

Double Blind Placebo ◽

Phase 2 Study ◽

Dose Ranging

OP0027 Itolizumab, A Human Anti-Cd6 Monoclonal Antibody, for Treatment of Rheumatoid Arthritis: Results of A Randomized, Placebo Controlled, Phase 2 Study

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.2818 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 69.3-70

Author(s):

A. Chopra ◽

C. Srikantiah ◽

P. Cg ◽

E. Montero ◽

R. Melarkode

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase 2 ◽

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Investigational New Drugs ◽

10.1007/s10637-012-9869-8 ◽

2012 ◽

Vol 31 (3) ◽

pp. 760-768 ◽

Cited By ~ 143

Author(s):

Kenneth J. Pienta ◽

Jean-Pascal Machiels ◽

Dirk Schrijvers ◽

Boris Alekseev ◽

Mikhail Shkolnik ◽

...

Keyword(s):

Prostate Cancer ◽

Monoclonal Antibody ◽

Human Monoclonal Antibody ◽

Phase 2 ◽

Castration Resistant Prostate Cancer ◽

Castration Resistant ◽

Phase 2 Study ◽

Chemokine Ligand ◽

Cc Chemokine Ligand 2 ◽

Chemokine Ligand 2

PURE01: An open label, single-arm, phase 2 study of the anti-programmed death (PD)-1 monoclonal antibody (moAb) pembrolizumab for neoadjuvant therapy of muscle-invasive urothelial bladder carcinoma (miUBC)

Annals of Oncology ◽

10.1093/annonc/mdw373.74 ◽

2016 ◽

Vol 27 ◽

pp. vi294

Author(s):

A. Necchi ◽

L. Mariani ◽

A. Anichini ◽

P. Giannatempo ◽

D. Raggi ◽

...

Keyword(s):

Monoclonal Antibody ◽

Neoadjuvant Therapy ◽

Bladder Carcinoma ◽

Phase 2 ◽

Open Label ◽

Urothelial Bladder Carcinoma ◽

Programmed Death ◽

Phase 2 Study ◽

Urothelial Bladder ◽

Muscle Invasive

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Arthritis & Rheumatology ◽

10.1002/art.38617 ◽

2014 ◽

Vol 66 (7) ◽

pp. 1693-1704 ◽

Cited By ~ 137

Author(s):

Mark C. Genovese ◽

Maria Greenwald ◽

Chul-Soo Cho ◽

Alberto Berman ◽

Ling Jin ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Randomized Study ◽

Biologic Agents ◽

Interleukin 17 ◽

Inadequate Response ◽

Tumor Necrosis Factor Inhibitors ◽

Necrosis Factor